2022 American Transplant Congress
Impact of Sub-therapeutic Tacrolimus Troughs at Discharge from Index Admission on Short-Term Outcomes in Kidney Transplant Recipients Receiving Rabbit Anti-Thymocyte Globulin Induction
*Purpose: Kidney transplant (KTx) recipients are often discharged with subtherapeutic tacrolimus (TAC) troughs due to short hospital lengths of stay (LOS) for index KTx admissions.…2022 American Transplant Congress
Prevention of the Progression in Chronic Calcineurin Inhibitors Nephrotoxicity via Steroids Anti-Inflammatory Effects
*Purpose: Calcineurin inhibitors (CNI) lead to an excellent short-term kidney allograft outcome. However, chronic nephrotoxicity is a major concern, which affects a long-term allograft survival.…2022 American Transplant Congress
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
*Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…2022 American Transplant Congress
Detection of Early Graft Injury After Liver Transplantation with Blood-Bile Ratio of Tacrolimus: The TUBE Trial
*Purpose: The aim of the“Tacrolimus in Bile”(TUBE)Trial is the creation of a laboratory parameter for the early detection of hepatic injury after liver transplant.*Methods: TUBE…2022 American Transplant Congress
Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients
*Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…2022 American Transplant Congress
Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model
Seoul St.Mary's Hospital, Seoul, Korea, Republic of
*Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…2022 American Transplant Congress
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
*Purpose: Our study hypothesis was that once daily dosing of extended-release tacrolimus (ERT) would be a safe and effective immunosuppression (IS) with the potential to…
- 1
- 2
- 3
- …
- 14
- Next Page »